Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Aging Clin Exp Res ; 34(3): 643-652, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34448150

RESUMO

BACKGROUND: Surgical aortic valve replacement (SAVR) is still the gold standard for treating aortic valve stenosis (AVS). Its effectiveness has been extensively examined in terms of perioperative mortality, but its impact on overall health has received much less attention. AIMS: To assess the physical performance, cognitive status, and health-related quality of life of elderly patients undergoing SAVR, in the short, medium and long term. METHODS: This single-center prospective study enrolled patients aged > 70 years who underwent isolated SAVR for severe AVS. Data were collected on each participant's clinical status, physical performance, cognitive status, mood, and health-related quality of life. This multidimensional geriatric assessment was performed before surgery (T0), and again at 45 days (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Baseline (T0) and follow-up (T2-T4) data were compared separately for patients grouped by gender using paired t-tests. RESULTS: Data from a total of 35 patients were analyzed. Compared with the baseline (T0), nutritional status worsened at T1, then gradually improved through to T4. Physical performance, mood, and health-related quality of life improved significantly after surgery. Cognitive function showed no change through to T3, but then deteriorated at T4. CONCLUSIONS: Our results show that SAVR in patients over 70 years of age has a positive impact on nutrition, mood, and health-related quality of life. Cognitive function was not negatively affected in the short and medium term, although it deteriorated in the long term. SAVR also had a positive impact on the physical performance of our sample.


Assuntos
Estenose da Valva Aórtica , Implante de Prótese de Valva Cardíaca , Substituição da Valva Aórtica Transcateter , Idoso , Idoso de 80 Anos ou mais , Valva Aórtica/cirurgia , Estenose da Valva Aórtica/cirurgia , Cognição , Implante de Prótese de Valva Cardíaca/efeitos adversos , Implante de Prótese de Valva Cardíaca/métodos , Humanos , Desempenho Físico Funcional , Estudos Prospectivos , Qualidade de Vida , Fatores de Risco , Resultado do Tratamento
2.
Nutr Metab Cardiovasc Dis ; 30(9): 1452-1464, 2020 08 28.
Artigo em Inglês | MEDLINE | ID: mdl-32600955

RESUMO

BACKGROUND AND AIMS: The influence of metabolic syndrome (MetS) on mortality may be influenced by age- and gender-related changes affecting the impact of individual MetS components. We investigated gender differences in the association between MetS components and mortality in community-dwelling older adults. METHODS AND RESULTS: Prospective studies were identified through a systematic literature review up to June 2019. Random-effect meta-analyses were run to estimate the pooled relative risk (RR) and 95% confidence intervals (95% CI) of all-cause and cardiovascular (CV) mortality associated with the presence of MetS components (abdominal obesity, high triglycerides, low HDL cholesterol, high fasting glycemia, and high blood pressure) in older men and women. Meta-analyses considering all-cause (103,859 individuals, 48,830 men, 55,029 women; 10 studies) and CV mortality (94,965 individuals, 44,699 men, 50,266 women; 8 studies) did not reveal any significant association for abdominal obesity and high triglycerides in either gender. Low HDL was associated with increased all-cause (RR = 1.16, 95% CI: 1.02-1.32) and CV mortality (RR = 1.34, 95% CI: 1.03-1.74) among women, while weaker results were found for men. High fasting glycemia was associated with higher all-cause mortality in older women (RR = 1.35, 95% CI: 1.22-1.50) more than in older men (RR = 1.21, 95% CI: 1.13-1.30), and CV mortality only in the former (RR = 1.36, 95% CI: 1.04-1.78). Elevated blood pressure was associated with increased all-cause mortality (RR = 1.16, 95% CI: 1.03-1.32) and showed marginal significant results for CV death only among women. CONCLUSIONS: The impact of MetS components on mortality in older people present some gender differences, with low HDL cholesterol, hyperglycemia, and elevated blood pressure being more strongly associated to all-cause and CV mortality in women.


Assuntos
Dislipidemias/mortalidade , Disparidades nos Níveis de Saúde , Hiperglicemia/mortalidade , Hipertensão/mortalidade , Síndrome Metabólica/mortalidade , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Glicemia/metabolismo , Pressão Sanguínea , Causas de Morte , Dislipidemias/sangue , Dislipidemias/diagnóstico , Feminino , Humanos , Hiperglicemia/sangue , Hiperglicemia/diagnóstico , Hipertensão/diagnóstico , Hipertensão/fisiopatologia , Lipídeos/sangue , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/diagnóstico , Síndrome Metabólica/fisiopatologia , Prognóstico , Medição de Risco , Fatores de Risco , Fatores Sexuais , Fatores de Tempo
3.
J Clin Densitom ; 23(3): 381-389, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31350204

RESUMO

BACKGROUND: Smoking is recognized among the risk factors for osteoporosis, but only few studies have comprehensively explored its influence on bone metabolism and strength. We aimed to evaluate smoking effects on calcium-phosphate metabolism, bone mineral density (BMD) and fracture risk in postmenopausal women. METHODS: Our sample included 1067 postmenopausal women who arrived to our osteoporosis outpatient clinic. Anamnestic data, smoking habits (categorized as never, former, and current; and by smoking intensity and duration), biochemical parameters, lumbar/femoral BMD, and presence of vertebral fractures were recorded. In a subsample of 357 women, the changes in BMD after a 2-yr follow-up period were also assessed. RESULTS: Current smokers had shorter reproductive age, lower body mass index, and higher prevalence of heavy alcohol consumption than former/never smokers. They also had lower PTH values and weaker linear association between serum vitamin D and parathyroid hormone (current ß = -0.11[SE = 0.004]; former ß = -0.14[SE = 0.01]; never ß = -0.20[SE = 0.003]; p < 0.01 for all). Baseline BMD did not reflect differences based on smoking habits, duration or intensity. However, after 2 years, only current smokers significantly worsened in femural BMD. After adjustment for confounders, the chance of having sustained vertebral fractures at the first evaluation increased by 74% (95% confidence interval:1.07-2.83) in current compared with never smokers, especially among heavy smokers. CONCLUSIONS: Smoking may negatively affect bone by inhibiting vitamin D-parathyroid hormone axis, reducing estrogen exposure, promoting risky health behaviors, and accelerating bone loss, especially at the femur. No significant differences were observed in these outcomes among former smokers, suggesting that quitting smoking has beneficial effects on bone health.


Assuntos
Densidade Óssea , Fumar Cigarros/epidemiologia , Osteoporose Pós-Menopausa/epidemiologia , Fraturas por Osteoporose/epidemiologia , Fraturas da Coluna Vertebral/epidemiologia , Idoso , Fumar Cigarros/sangue , Ex-Fumantes , Feminino , Fêmur/diagnóstico por imagem , Humanos , Pessoa de Meia-Idade , não Fumantes , Osteoporose/sangue , Osteoporose/diagnóstico por imagem , Osteoporose/epidemiologia , Osteoporose Pós-Menopausa/sangue , Osteoporose Pós-Menopausa/diagnóstico por imagem , Hormônio Paratireóideo/sangue , Pós-Menopausa , Fumantes , Produtos do Tabaco , Vitamina D/análogos & derivados , Vitamina D/sangue
4.
J Low Genit Tract Dis ; 18(1): E4-11, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23959295

RESUMO

OBJECTIVE: This study aimed to identify the best management options in decision making in cases of cervicoisthmic and cesarean scar pregnancies and rare forms of ectopic pregnancies with high rates of pregnancy-related morbidity in the first trimester, more commonly associated with assisted reproductive medicine. MATERIALS AND METHODS: We performed a literature review of the description of a case report of a cervicoisthmic pregnancy near a cesarean scar in a premature ovarian failure woman. She obtained pregnancy after ovum donation, hormonal therapy, and in vitro fertilization. The researchers focused on the MEDLINE/PubMed database articles on ectopic pregnancies, particularly on cesarean scar pregnancies, cervical pregnancies, and ectopic pregnancies after in vitro fertilization in English-language journals published from January 1996 to December 2011. RESULTS: The conservative or nonconservative options for medical or surgical treatments are disposables. Moreover, in literature, no consensus was found about the best treatment method. CONCLUSIONS: Obstetricians should pay great attention to a possible cesarean scar pregnancy in patients with risk factors in their medical history. Until now, the rarity of these findings does not allow the definition of a commonly accepted management, so the best personalized approach may be guided by early recognition, close surveillance, and appropriate counseling. Further investigations are necessary to recognize high-risk factors for all ectopic pregnancies and those unique to cesarean scar ectopic pregnancies.


Assuntos
Gravidez Ectópica/diagnóstico , Gravidez Ectópica/terapia , Adulto , Feminino , Humanos , Doação de Oócitos , Gravidez , Insuficiência Ovariana Primária
5.
Minim Invasive Ther Allied Technol ; 23(2): 115-9, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24024657

RESUMO

The aim of this report was to define the best diagnostic and therapeutic approach when secondary amenorrhea is related to undiagnosed Asherman syndrome. We present a single case of secondary amenorrhea with a previous diagnosis of alterated hypothalamic-hypophysary regulation, with a component of ovarian function in probable reduction, which was evaluated in our department and resulted affected by Asherman's syndrome IV stage. We describe step by step the diagnosis and treatment of a previously misdiagnosed case of severe Asherman's syndrome. An appropriate diagnosis and adequate treatment are mandatory to allow menses and fertility to be restored when severe Asherman's syndrome occurs.


Assuntos
Amenorreia/etiologia , Fertilidade , Ginatresia/complicações , Ginatresia/diagnóstico , Histeroscopia/métodos , Adulto , Diagnóstico Diferencial , Feminino , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo
6.
Minim Invasive Ther Allied Technol ; 23(5): 261-70, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24678788

RESUMO

PURPOSE: The aim of this review is to compare studies concerning female sterilization in order to define the most suitable approach and device for each patient considering timing, safety, cost-effectiveness, failure rate, complication rate and patient satisfaction. METHODS: A systematic literature search was conducted in electronic databases MEDLINE-EMBASE-Sciencedirect and Cochrane Library between 2000 and 2012. All original descriptions, case reports, retrospective and review articles on tubal sterilization methods have been considered. Outcome measures were effectiveness, tolerability, procedure complications and female satisfaction. RESULTS: The ideal female sterilization system should be a simple, safe, highly efficient, easily learned, inexpensive, one-time procedure without negative side-effects. Nowadays, the trans-cervical approach is associated with minimal postoperative pain, allowing short hospitalization and fast resumption of daily activities. Laparoscopic and laparotomic approaches are considered second choices, since, particularly in developing countries, the transcervical hysteroscopic methods will increasingly spread within gynaecological clinical practice. CONCLUSIONS: Safety issues, hospital stay, costs and surgeons' experience are important factors in decision-making of the method for female sterilization. Hysteroscopic devices should be preferred when possible. The counselling time remains a fundamental step in choice. The decision concerning method depends on the setting, the surgeon's experience, the country's economical development and the woman's preference.


Assuntos
Laparoscopia/métodos , Laparotomia/métodos , Esterilização Reprodutiva/métodos , Contraindicações , Análise Custo-Benefício , Países Desenvolvidos , Feminino , Humanos , Histeroscopia/métodos , Dor Pós-Operatória/epidemiologia , Satisfação do Paciente , Complicações Pós-Operatórias/epidemiologia , Esterilização Reprodutiva/efeitos adversos
7.
Exp Gerontol ; 187: 112382, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38369251

RESUMO

BACKGROUND: Coronavirus Disease-2019 (COVID-19), driven by the SARS-CoV-2 virus, has disproportionately affected the elderly, with comorbidities like sarcopenia worsening prognosis. Considering the significant impact of RNA vaccines on survival rates in this population, our objective is to investigate the impact of vaccination on the survival of hospitalized elderly patients with COVID-19, considering the presence or absence of sarcopenia. METHODS: Prospective study conducted on 159 patients aged>65 years from September 2021 to March 2022. Data about clinical and body composition, and mortality at 12-months after discharge were recorded. Sarcopenia was diagnosed according to the 2019 European Consensus criteria. RESULTS: At the twelfth month post-discharge, vaccinated sarcopenic individuals exhibited a mortality risk similar to vaccinated non-sarcopenic individuals, and lower than unvaccinated non-sarcopenic patients. Cox regression analysis, adjusted for age, gender, comorbidity, functional and vaccinal status, showed that the presence of sarcopenia did not significantly impact the risk of death within 12-months post-discharge. DISCUSSION: Vaccination emerges as a protective measure for sarcopenic patients, countering the potential adverse effects of sarcopenia on COVID-19 outcomes, underscoring the importance of immunization in the frail elderly with a call for meticulous monitoring of its benefits. CONCLUSIONS: Our study represents the first attempt to analyze the vaccine's effect on survival in sarcopenic hospitalized older adults with COVID-19. The administration of vaccination to sarcopenic patients proves pivotal, as its omission could lead to notably unfavorable outcomes within this specific population.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Sarcopenia , Idoso , Humanos , Assistência ao Convalescente , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Alta do Paciente , Estudos Prospectivos , SARS-CoV-2 , Vacinação
8.
J Pers Med ; 14(5)2024 Apr 28.
Artigo em Inglês | MEDLINE | ID: mdl-38793051

RESUMO

Chronic rhinosinusitis with nasal polyps (CRSwNP) in the severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with Dupilumab in different rhinological units were considered for this study via their evaluation at the baseline at first and the consequential follow-up at 6-, 12-, and 24 months from the first administration. At baseline (T0) and at each follow-up, patients underwent NPS, Sinonasal Outcome Test (SNOT)-22, Visual Analogue Scale (VAS) for smell, and Sniffin' sticks identification test (SSIT). The SNOT-22 domains for function and emotion were also analysed separately. Two hundred and seventeen patients with at least 6 months of follow-up were included. All parameters have improved during treatment (p < 0.0001). Noticeably, both the function and emotion SNOT-22 domains have improved within 6 months of treatment and have continued to progress during every interval within 12 months from the baseline, positively influencing patients' emotivity and augmenting their social and economic performances. Dupilumab improves the QoL of CRSwNP patients with good effects on the reported productivity and emotional health. Clinicians should pay attention to these two aspects when dealing with patients affected by severe CRSwNP.

9.
Exp Gerontol ; 122: 47-52, 2019 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-31028839

RESUMO

OBJECTIVES: The aim of this prospective study was to investigate whether two cellular and metabolic health indices, phase angle (PhA) and metabolic equivalents (METs), can predict changes in frailty states in fit community-dwelling older people. METHODS: A sample of 118 individuals aged ≥65 years who attended a twice-weekly mild fitness program of aerobic and/or resistance exercises was enrolled in the study. At baseline and after three years, individuals underwent a clinical examination, biochemical determinations, bioelectrical impedance analysis, body composition assessment with dual energy X-ray absorptiometry, physical performance tests, and frailty and sarcopenia assessment. In 78 participants was executed indirect calorimetry, too. Based on frailty transitions during the follow-up between non-frailty, pre-frailty and frailty, participants were categorized as improved, stable (non-frail or pre-frail), and worsened or remaining frail. The chances to experience different frailty changes by baseline PhA and METs were explored through multinomial regression analysis and expressed as odds ratios (OR) and 95% Confidence intervals (95%CI). RESULTS: During the follow-up, 8 participants improved in frailty status, 84 were stable and 26 worsened or remained frail. For each one-unit increase in PhA, the odds of improving in frailty increased by 4.53 times (95%CI:1.18-17.46); while for each one-unit increase in METs, the odds of worsening in frailty decreased by 65% (95%CI:0.16-0.79). CONCLUSIONS: PhA and METs may be indirect measures of functional reserve, with lower values being potential biomarkers of evolving frailty.


Assuntos
Impedância Elétrica , Fragilidade/diagnóstico , Equivalente Metabólico , Sarcopenia/diagnóstico , Absorciometria de Fóton , Idoso , Feminino , Fragilidade/fisiopatologia , Avaliação Geriátrica , Humanos , Modelos Lineares , Modelos Logísticos , Masculino , Estudos Prospectivos , Sarcopenia/fisiopatologia
10.
Maturitas ; 100: 8-15, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28539181

RESUMO

Low serum levels of 25 hydroxyvitamin D (25OHD) (hypovitaminosis D) is common in older adults and associated with several negative outcomes. The association between hypovitaminosis D and diabetes in older adults is equivocal, however. We conducted a meta-analysis investigating if hypovitaminosis D is associated with diabetes in prospective studies among older participants. Two investigators systematically searched major electronic databases, from inception until 10/07/2016. The cumulative incidence of diabetes among groups was estimated according to baseline serum 25OHD levels. Random effect models were used to assess the association between hypovitaminosis D and diabetes at follow-up. From 4268 non-duplicate hits, 9 studies were included; these followed 28,258 participants with a mean age of 67.7 years for a median of 7.7 years. Compared with higher levels of 25OHD, lower levels of 25OHD were associated with a higher risk of developing diabetes (6 studies; n=13,563; RR=1.31; 95% CI: 1.11-1.54; I2=37%). The findings remained significant after adjusting for a median of 11 potential confounders in all the studies available (9 studies; n=28,258; RR=1.17; 95% CI: 1.03-1.33; p=0.02; I2=0%). In conclusion, our data suggest that hypovitaminosis D is associated with an elevated risk of future diabetes in older people. Future longitudinal studies are required and should seek to confirm these findings and explore potential pathophysiological underpinnings.


Assuntos
Diabetes Mellitus Tipo 2/epidemiologia , Deficiência de Vitamina D/sangue , Vitamina D/sangue , Vitaminas/sangue , Adulto , Diabetes Mellitus Tipo 2/sangue , Humanos , Risco
11.
Reprod Sci ; 21(4): 423-31, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24060633

RESUMO

Levonorgestrel intrauterine system (LNG-IUS) is used in patients with breast patients taking tamoxifen (TAM) to prevent endometrial proliferation. The benefits (on endometrium), the side effects (on breast), and the patients suitable for this treatment are not still clear. Aim of this systematic review is to define the breast risks and endometrial benefits in TAM-treated women using Mirena and to define which patients could benefit from LNG-IUS use. In all, 3 studies on LNG-IUS effects on endometrium in TAM-treated women and 4 studies on breast cancer recurrence were selected for the study. All studies described a reduction in benign endometrial pathologies among Mirena users, but controversial data showed malignant disease and breast cancer recurrence. So it is mandatory to define hormonal status before TAM treatment. In selected patients Mirena was proven to protect endometrium. Perspective clinical trials on Mirena pharmacological features are necessary to establish whether systemic levels of progesterone could increase breast cancer recurrence in such patients.


Assuntos
Antineoplásicos Hormonais/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Proliferação de Células/efeitos dos fármacos , Endométrio/efeitos dos fármacos , Dispositivos Intrauterinos Medicados , Levanogestrel/administração & dosagem , Levanogestrel/efeitos adversos , Recidiva Local de Neoplasia , Tamoxifeno/efeitos adversos , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Endométrio/metabolismo , Endométrio/patologia , Feminino , Humanos , Seleção de Pacientes , Progesterona/sangue , Medição de Risco , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento
12.
Fertil Steril ; 99(2): 496-501, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23127591

RESUMO

OBJECTIVE: To define the role of lower uterine segment (LUS) evaluation at term. DESIGN: Observational case-control study. SETTING: University hospital. PATIENT(S): Ninety-four patients were divided into two groups. Group A consisted of 45 multiparous single fetus pregnant women with up to two previous cesarean sections (CS). Group B consisted of 49 multiparous pregnant women with up to three vaginal deliveries and no uterine scars. INTERVENTION(S): Total LUS and myometrial thickness were measured by sonogram in all patients before undergoing a CS. MAIN OUTCOME MEASURE(S): The primary outcome is a correlation between echographic measurements and features of the LUS at the time of CS. The secondary outcome is a definition of a correlation between the number of previous CS, interdelivery interval time, and features of the LUS (grades I-IV). RESULT(S): Sonographic measurements revealed significant differences in LUS size and myometrial thickness between the two groups. Grades III and IV of LUS were only observed in group A. An interdelivery interval <18 months, LUS thickness ≤ 3.0 mm, and myometrial thickness < 1.5 mm were statistically significant predictors of LUS grades III and IV. Number of previous CS showed no correlation with surgical LUS status. CONCLUSION(S): Sonographic evaluation of the LUS may be a noninvasive, reproducible, and safe technique for defining the risk of uterine dehiscence, with a sensitivity of 100% and specificity of 85% (positive predictive value, 45%; negative predictive value, 100%).


Assuntos
Cesárea/efeitos adversos , Complicações na Gravidez/diagnóstico por imagem , Deiscência da Ferida Operatória/diagnóstico por imagem , Deiscência da Ferida Operatória/etiologia , Doenças Uterinas/diagnóstico por imagem , Doenças Uterinas/etiologia , Adolescente , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Paridade , Gravidez , Complicações na Gravidez/etiologia , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Ultrassonografia , Nascimento Vaginal Após Cesárea , Adulto Jovem
13.
Reprod Sci ; 20(9): 1011-9, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23296037

RESUMO

BACKGROUND: Postpartum hemorrhage (PPH) is a potentially fatal complication of vaginal and cesarean deliveries. The active management of the third stage of labor provides administration of prophylactic uterotonic drugs just before or immediately after delivery, since they reduce the risk of PPH by 60%. OBJECTIVE: Overview on all available uterotonics for PPH prevention to clarify indications and contraindications in choice among drugs. SEARCH STRATEGY: Systematic review of the literature. MAIN RESULTS: Oxytocin is the first choice for PPH prophylaxis. Ergot alkaloids, syntometrine, and prostaglandins are second-line uterotonic agents. Misoprostol is not effective as oxytocin but it may be used when the latter is not available. Carbetocin should be used instead of continuous oxytocin infusion in elective cesarean sections for PPH prevention and to decrease the need for therapeutic uterotonics. CONCLUSIONS: Prophylactic oxytocics should be offered routinely in the third stage of labor in all women. The prophylactic use of uterotonics should be individualized.


Assuntos
Ocitócicos/uso terapêutico , Hemorragia Pós-Parto/prevenção & controle , Animais , Contraindicações , Esquema de Medicação , Feminino , Humanos , Terceira Fase do Trabalho de Parto , Ocitócicos/administração & dosagem , Ocitócicos/efeitos adversos , Guias de Prática Clínica como Assunto , Gravidez , Resultado do Tratamento
14.
Oncol Rep ; 30(6): 2545-54, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24065029

RESUMO

Radical trachelectomy (RT) can be performed vaginally or abdominally (laparotomic, laparoscopic or robotic). The aim of this systematic review was to compare all techniques in terms of surgical complications, disease recurrence and subsequent fertility/pregnancy outcomes. A total of 1293 RTs were analyzed (FIGO-stage: IA1-IIA). The most frequent surgical complications do not differ from the ones of radical hysterectomy. The recurrence risk is approximately 3% (range 0-16.8%). The majority of women conceive spontaneously: 284 pregnancies with 173 live births. The most frequent pregnancy complication was miscarriage and chorioamnionitis. RT appears to be a safe option for eligible women who intend to maintain their future pregnancy desire.


Assuntos
Fertilidade , Histerectomia , Complicações Neoplásicas na Gravidez/cirurgia , Neoplasias do Colo do Útero/cirurgia , Feminino , Humanos , Nascido Vivo , Estadiamento de Neoplasias , Gravidez , Complicações Neoplásicas na Gravidez/patologia , Resultado do Tratamento , Neoplasias do Colo do Útero/complicações , Neoplasias do Colo do Útero/patologia
15.
Obstet Gynecol Surv ; 68(6): 467-81, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23942473

RESUMO

Raloxifene is the only selective estrogen receptor modulator approved for long-term treatment in the prevention of osteoporotic fractures and for the reduction of invasive breast cancer risk in post-menopausal women. The demonstrated beneficial effects on bone and mammalian tissue led clinical and molecular research to focus mainly on these organs, giving less attention to all other systemic effects. The aim of this review was to evaluate all described systemic effects of raloxifene, investigating its molecular and tissutal mechanism of action. A literature research was carried out in electronic databases MEDLINE, EMBASE, ScienceDirect, and the Cochrane Library in interval time between 2000 and 2012. Outcomes were considered in relation to positive/adverse effects concerning bone metabolism, lipid metabolism, coagulation pattern, menopausal symptoms, breast cancer onset, and endometrial cancer onset. Raloxifene acts as an estrogen agonist or antagonist depending on the tissue. This feature is related to specific actions on at least 2 distinct estrogen receptors, whose proportions vary according to tissue type. Raloxifene is a drug for the treatment of osteoporosis and for the prevention of estrogen receptor-positive breast cancer because it guarantees a safety profile on the endometrium. Raloxifene is furthermore an effective therapy in women with increased levels of plasma cholesterol. Raloxifene treatment shifts the coagulation pattern toward prothrombosis, and the patients should be exhaustively informed about the risks associated with therapy. Raloxifene does not show to affect memory and cognition. Finally, it is noteworthy that quality-of-life studies demonstrated some favorable effects of raloxifene.


Assuntos
Neoplasias da Mama/prevenção & controle , Osteoporose/tratamento farmacológico , Cloridrato de Raloxifeno/farmacologia , Cloridrato de Raloxifeno/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/farmacologia , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Coagulação Sanguínea/efeitos dos fármacos , Osso e Ossos/efeitos dos fármacos , Mama/efeitos dos fármacos , Neoplasias da Mama/química , Contraindicações , Endométrio/efeitos dos fármacos , Feminino , Humanos , Hipercolesterolemia/complicações , Hipercolesterolemia/tratamento farmacológico , Osteoporose/complicações , Receptores de Estrogênio/análise , Fatores de Risco , Tromboembolia/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA